Fred Alger Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$208K Sell
3,690
-1,865
-34% -$109K ﹤0.01% 433
2025
Q4
$330K Sell
5,555
-18,145
-77% -$988K ﹤0.01% 414
2025
Q3
$1.28M Sell
23,700
-4,907
-17% -$281K 0.01% 345
2025
Q2
$1.57M Sell
28,607
-196
-0.7% -$11.5K 0.01% 329
2025
Q1
$2.04M Buy
28,803
+2,933
+11% +$197K 0.01% 299
2024
Q4
$1.7M Sell
25,870
-703
-3% -$47.1K 0.01% 342
2024
Q3
$1.87M Sell
26,573
-2,943
-10% -$246K 0.01% 330
2024
Q2
$2.43M Sell
29,516
-1,664
-5% -$139K 0.01% 310
2024
Q1
$2.72M Sell
31,180
-2,209
-7% -$198K 0.01% 318
2023
Q4
$3.22M Sell
33,389
-7,493
-18% -$663K 0.02% 289
2023
Q3
$3.62M Sell
40,882
-6,715
-14% -$597K 0.02% 274
2023
Q2
$4.13M Sell
47,597
-85,326
-64% -$8.03M 0.02% 267
2023
Q1
$12.9M Buy
132,923
+60,297
+83% +$6.25M 0.07% 180
2022
Q4
$7.52M Buy
72,626
+33,940
+88% +$3.19M 0.04% 231
2022
Q3
$3.28M Sell
38,686
-32,718
-46% -$2.91M 0.02% 289
2022
Q2
$5.92M Sell
71,404
-51,391
-42% -$4.09M 0.03% 247
2022
Q1
$9.47M Sell
122,795
-93,055
-43% -$7.79M 0.03% 225
2021
Q4
$19.1M Buy
215,850
+174,998
+428% +$14.4M 0.05% 211
2021
Q3
$3.16M Buy
40,852
+2,701
+7% +$213K 0.01% 321
2021
Q2
$3.18M Buy
38,151
+7,711
+25% +$611K 0.01% 329
2021
Q1
$2.3M Sell
30,440
-415,970
-93% -$34M 0.01% 338
2020
Q4
$39.1M Buy
446,410
+66,567
+18% +$5.28M 0.1% 160
2020
Q3
$28.9M Sell
379,843
-853,768
-69% -$86.4M 0.08% 151
2020
Q2
$152M Buy
1,233,611
+1,215,604
+6,751% +$121M 0.5% 50
2020
Q1
$1.52M Buy
18,007
+6,937
+63% +$598K 0.01% 293
2019
Q4
$936K Buy
11,070
+4,314
+64% +$326K ﹤0.01% 349
2019
Q3
$455K Sell
6,756
-13,247
-66% -$1.02M ﹤0.01% 374
2019
Q2
$1.71M Buy
20,003
+3,553
+22% +$304K 0.01% 299
2019
Q1
$1.46M Sell
16,450
-672,286
-98% -$62.3M 0.01% 302
2018
Q4
$58.6M Sell
688,736
-164,677
-19% -$15.7M 0.27% 83
2018
Q3
$82.8M Sell
853,413
-121,060
-12% -$12.1M 0.31% 79
2018
Q2
$91.8M Buy
974,473
+39,852
+4% +$3.49M 0.39% 53
2018
Q1
$75.8M Sell
934,621
-89,411
-9% -$7.67M 0.35% 63
2017
Q4
$91.3M Buy
1,024,032
+3,793
+0.4% +$330K 0.41% 63
2017
Q3
$95M Sell
1,020,239
-8,790
-0.9% -$777K 0.44% 56
2017
Q2
$93.5M Sell
1,029,029
-84,226
-8% -$7.66M 0.45% 59
2017
Q1
$97.7M Buy
1,113,255
+28,122
+3% +$2.5M 0.49% 52
2016
Q4
$89.9M Sell
1,085,133
-559,696
-34% -$48.1M 0.49% 53
2016
Q3
$152M Buy
1,644,829
+209,042
+15% +$19.7M 0.78% 30
2016
Q2
$112M Buy
1,435,787
+196,503
+16% +$16.7M 0.59% 44
2016
Q1
$102M Buy
1,239,284
+860,439
+227% +$70M 0.52% 53
2015
Q4
$39.7M Sell
378,845
-260,586
-41% -$27.2M 0.19% 92
2015
Q3
$67.3M Sell
639,431
-219,973
-26% -$29.4M 0.37% 71
2015
Q2
$118M Buy
859,404
+289,873
+51% +$35.9M 0.53% 56
2015
Q1
$71M Buy
569,531
+493,871
+653% +$52.3M 0.32% 87
2014
Q4
$6.84M Buy
75,660
+7,125
+10% +$593K 0.03% 306
2014
Q3
$4.95M Sell
68,535
-36,274
-35% -$2.38M 0.02% 342
2014
Q2
$6.52M Sell
104,809
-109,175
-51% -$6.6M 0.03% 334
2014
Q1
$14.6M Sell
213,984
-56,075
-21% -$4.13M 0.07% 258
2013
Q4
$19M Buy
270,059
+161,642
+149% +$11M 0.1% 223
2013
Q3
$7.82M Buy
108,417
+73,179
+208% +$4.86M 0.04% 308
2013
Q2
$1.96M Buy
+35,238
New +$2.2M 0.01% 390

Other funds holding BMRN

Fred Alger Management's BMRN Position: Q1 2026 in Review

Fred Alger Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q1 2026, selling an estimated $109K and leaving 3,690 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #433.

Fred Alger Management first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $152M in Q3 2016. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Fred Alger Management held 3,690 shares of BioMarin Pharmaceuticals worth $208K as of Q1 2026.
  • Fred Alger Management sold 1,865 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $109K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #433 holding.
  • Fred Alger Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Fred Alger Management's BioMarin Pharmaceuticals position peaked at $152M in Q3 2016.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.